07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Molecular Dynamics, Amersham Pharmacia Biotech plc, DuPont Agricultural Products deal

MDYN and partner Amersham Pharmacia Biotech will include DuPont Agricultural Products in their Microarray Technology Access program. DuPont will use the microarray system to study gene expression in agricultural seed and plant species and to...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Nova Molecular Inc., Amersham Pharmacia Biotech Ltd. deal

Amersham made a minority equity investment in Nova Molecular in return for rights to a pharmacogenomic sequencing project being done by Nova and McGill University (Montreal, Quebec). The project is identifying variants in four genes...
07:00 , Apr 28, 2003 |  BioCentury  |  Emerging Company Profile

Norak: Blocking desensitization

After selling Medco Research Inc. to King Pharmaceuticals Inc. in late 1999, Roger Blevins called Duke University looking for an interesting technology to build a new company around. The result is Norak Biosciences Inc. ,...
07:00 , Sep 23, 2002 |  BC Week In Review  |  Company News

Amersham, Pharmacia, Novartis deal

AHM's Amersham Biosciences division (Piscataway, N.J.) licensed to NVS and PHA rights to green fluorescent protein (GFP) vectors for drug discovery research. GFP vectors, which are derived from jellyfish, can detect interaction with a GFP-linked...
08:00 , Mar 18, 2002 |  BC Week In Review  |  Company News

Amersham, Pharmacia, University of Washington deal

PHA will sell to AHM its 45% holding in Amersham Biosciences plc (Little Chalfont, U.K.) for L704 million ($1 billion) in cash, giving AHM 100% ownership of the joint venture. Amersham Biosciences, formerly Amersham Pharmacia...
08:00 , Mar 12, 2002 |  BC Extra  |  Company News

AHM buys PHA's APBiotech stake

Pharmacia (PHA) will sell to Amersham (AHM; LSE:AHM) its 45% holding in Amersham Biosciences (Little Chalfont, U.K.) for L704 million ($1 billion) in cash, giving AHM 100% ownership of the joint venture. PHA said the...
07:00 , Oct 22, 2001 |  BC Week In Review  |  Company News

Karo Bio management update

Karo Bio AB (SSE:KARO), Stockholm, Sweden   Business: Genomics, Metabolic   Hired: Mats Johnson as VP of marketing and business development, formerly VP of proteomics at Amersham Pharmacia Biotech; he replaces Marten Osterlund  ...
07:00 , Sep 17, 2001 |  BC Week In Review  |  Company News

Vertex, Amersham sales and marketing update

NYE life science business Amersham Pharmacia Biotech and VRTX subsidiary Aurora Biosciences Corp. will market their combined Green Fluorescent Protein (GFP) technologies for various applications in functional genomics, high throughput screening assays and gene profiling...
07:00 , Sep 10, 2001 |  BC Extra  |  Company News

Amersham, Aurora to market GFP technology

Amersham Pharmacia Biotech and Aurora will market their combined Green Fluorescent Protein (GFP) technology for various applications in functional genomics, high throughput screening assays and gene profiling to assess compounds' toxicity. Amersham Pharmacia is the...
07:00 , Sep 4, 2001 |  BC Week In Review  |  Company News

Norak, Nycomed Amersham plc deal

NYE business Amersham Pharmacia Biotech Inc. and Norak will combine their G protein-coupled receptor drug discovery technologies. The deal brings together Amersham Pharmacia's LEADSeeker Cell Analysis System for high throughput screening of live, whole cell...